Life Science News

RSS

New assay kits can screen epigenetic factors for drug discovery

At the Society for Neuroscience Annual Meeting, being held from November 13-17, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of a panel of epigenetics-based detection reagents to enable high-throughput screening (HTS) for new drug candidates. The new assay kits can screen for epigenetic factors to assist researching diseases such as neurodegeneration and cancer.

From PerkinElmer 16 Nov 2010

PerkinElmer to launch XRD 0822 and XRD 1622 Digital X-Ray Flat Panel Detectors for Non-Destructive Testing

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.

From PerkinElmer 15 Nov 2010

Roche, CapitalBio to initiate strategic partnership for molecular diagnostic applications

Roche Diagnostics and CapitalBio have announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide. This new development builds on the genomics and diagnostics expertise of the two companies and will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.

From Roche Diagnostics Limited 11 Nov 2010

Roche announces U.S. introduction of cobas e 602 analyzer

Roche announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas 8000 modular analyzer series for diagnostic labs with high-volume workloads. Labs will now be able to combine this new immunoassay module with two existing clinical chemistry modules to create an integrated platform with 24 unique system configurations to match their specific testing needs.

From Roche Diagnostics Limited 30 Oct 2010

PerkinElmer, LinaTech enter oncology technology development and marketing agreement

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has entered into a joint technology development and marketing agreement with LinaTech, a leading manufacturer of medical devices and software for treating cancer with radiotherapy.

From PerkinElmer 29 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Thermo Fisher 2010 third quarter revenue increases 6% to $2.68 billion

Thermo Fisher Scientific Inc. the world leader in serving science, today reported financial results for the third quarter ended October 2, 2010.

From Thermo Fisher Scientific Inc. 27 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

Panasonic completes investment in CardioNexus

Panasonic Corporation of North America has completed an investment in CardioNexus Corporation, a portfolio company of Houston's Fairway Medical Technologies which works closely with the Texas Medical Center. The move is part of Panasonic's plans to establish itself as a global leader in Personalized Preventive Medicine. The investment follows on an earlier Panasonic initiative to establish a presence in the world's largest medical complex, the Texas Medical Center based in Houston.

From PHC Europe B.V. 26 Oct 2010

Tecan, Luminex collaborate to develop automated newborn screening solution

The Tecan Group and Luminex Corporation have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns.

From Tecan 13 Oct 2010

Roche, DKFZ announce research collaboration to predict cervical cancer risk

Roche Molecular Systems, Inc. and the German Cancer Research Center announced today that they have entered into a research collaboration to enable more specific prediction of a woman's risk for developing cervical cancer.

From Roche Diagnostics Limited 11 Oct 2010

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Roche announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time.

From Roche Diagnostics Limited 29 Sep 2010

Olympus Healthcare Solutions declared HIPAA Compliant

Olympus Healthcare Solutions is pleased to announce that it has achieved Health Insurance Portability and Accountability Act Certification. Olympus Healthcare Solutions, which includes its Olympus Managed Health Care, Inc., Healthcare Concierge Services, and Axiom Risk Management operating units, is now among a prestigious group of organizations that comply with the HIPAA regulations.

From Olympus Life Science Solutions 24 Sep 2010

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused primarily on arthroplasty and trauma reconstruction technology and treatments for the small bones & joints, reported continuing growth for its S.T.A.R. ankle arthroplasty implant system with August being the biggest month ever for the S.T.A.R. in terms of revenues and surgeries.

From Olympus Life Science Solutions 17 Sep 2010

Fred Hutchinson Cancer Center research team wins 2010 BioFlux Innovation Award

Fluxion Biosciences, Inc. announced today that a research team from Fred Hutchinson Cancer Center has won the 2010 BioFlux Innovation Award competition. Laura Sycuro, Ph.D., a post-doctoral research fellow in the lab of David Fredricks, M.D., authored the winning submission which focuses on screening and characterizing bacterial strains involved in biofilm-related infections known to affect women's reproductive health.

From Fluxion Biosciences 17 Sep 2010

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

Roche Diagnostics announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes.

From Roche Diagnostics Limited 17 Sep 2010

Roche granted FDA 510(k) clearance for cobas 8000 modular analyzer series

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas® 8000 modular analyzer series, a Serum Work Area solution designed for diagnostic laboratories with a workload of 3-15 million clinical chemistry / immunochemistry tests per year.

From Roche Diagnostics Limited 14 Sep 2010

NEXUS Biosystems acquires REMP from Tecan Group

NEXUS Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, today announced the completion of the acquisition of REMP AG of Switzerland, a wholly-owned subsidiary of the Tecan Group.

From Tecan 8 Sep 2010

PerkinElmer divests Illumination and Detection Solutions business

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has agreed to sell its Illumination and Detection Solutions (IDS) business to Veritas Capital Fund III, L.P., a New York-based private equity firm, for approximately $500 million in cash ($482 million net of payment for acquired cash balances).

From PerkinElmer 2 Sep 2010

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

Luminex Corporation, the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

From Thermo Fisher Scientific Inc. 27 Aug 2010